Phase II results for Adolor's ADL 8-2698

ADLR reported results of two double-blind, placebo-controlled Phase II studies of its ADL 8-2698 gastrointestinal opioid antagonist in patients with opioid-induced bowel dysfunction. In a Phase II tri...